Valneva SE (NASDAQ:VALN – Get Rating)'s share price fell 4.1% on Tuesday . The company traded as low as $14.63 and last traded at $14.63. 2,420 shares were traded during mid-day trading, a decline of 42% from the average session volume of 4,201 shares. The stock had previously closed at $15.26.
Analyst Ratings Changes
Separately, HC Wainwright reduced their price objective on shares of Valneva from $27.00 to $25.00 in a research report on Monday, December 5th.
Get
Valneva alerts:
Valneva Stock Performance
The stock's 50-day moving average price is $13.95 and its 200 day moving average price is $15.43. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.02 and a current ratio of 1.27.
Valneva (NASDAQ:VALN – Get Rating) last issued its earnings results on Thursday, November 10th. The company reported $1.33 EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $1.47. The company had revenue of $157.92 million for the quarter, compared to analysts' expectations of $78.52 million. Sell-side analysts anticipate that Valneva SE will post -1.19 earnings per share for the current year.
Hedge Funds Weigh In On Valneva
A number of hedge funds and other institutional investors have recently modified their holdings of the business. UBS Group AG bought a new position in shares of Valneva during the second quarter valued at approximately $31,000. Jane Street Group LLC boosted its stake in shares of Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock valued at $569,000 after purchasing an additional 7,664 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Valneva during the first quarter valued at approximately $858,000. Finally, General American Investors Co. Inc. bought a new position in shares of Valneva during the third quarter valued at approximately $3,768,000. 15.83% of the stock is currently owned by institutional investors.
About Valneva
(Get Rating)
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.
Featured Stories
- Get a free copy of the StockNews.com research report on Valneva (VALN)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.
